PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...
Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.
The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...
Leveraging AI to help analyze and visualize data gathered from a variety of data sets enables data-driven insights and fast analysis without the high costs of talent and technology. In today's ...
Zacks Investment Research on MSN
BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study
Bristol Myers Squibb BMY announced positive data from the late-stage study on iberdomide in patients with relapsed or refractory multiple myeloma (RRMM). The phase III EXCALIBER-RRMM (NCT04975997) is ...
What if you could transform the way you analyze data in just 12 minutes? Picture this: a mountain of raw numbers and spreadsheets that once felt overwhelming now becomes a treasure trove of actionable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback